Table 1.

Clinical characteristics and treatment exposure of patients.

	Total (n=946)	biosimilar group (n=551)	reference group (n=395)	P
Sex
Male	533 (56.34%)	305 (55.35%)	228 (57.72%)	0.469
Female	413 (43.66%)	246 (44.65%)	167 (42.48%)
Age (years)
≥60	524 (55.39%)	303 (54.99%)	221 (55.95%)	0.770
<60	422 (44.61%)	248 (45.01%)	174 (44.05%)
Pathological type
adenocarcinoma	932 (98.52%)	543 (98.55%)	389 (98.48%)	0.933
Nonadenocarcinoma	14 (1.48%)	8 (1.45%)	6 (1.52%)
Stage of cancer
IIIB	54 (5.71%)	32 (5.81%)	22 (5.57%)	0.876
IV	892 (94.29%)	519 (94.19%)	373 (94.43%)
Gene mutation type
No genetic mutation	448 (48.41%)	247 (44.83%)	201 (50.89%)	0.066
EGFR exon 18 point mutation	4 (0.42%)	2 (0.36%)	2 (0.51%)	0.738
EGFR exon 19 deletion	162 (17.12%)	101 (18.33%)	61 (15.44%)	0.245
EGFR exon 20 insertion	24 (2.54%)	15 (2.72%)	9 (2.28%)	0.669
EGFR the L858R point mutation	209 (21.04%)	125 (22.69%)	84 (21.27%)	0.604
EGFR double mutation	10 (1.06%)	4 (0.73%)	6 (1.52%)	0.335
ALK rearrangement	26 (2.75%)	14 (2.54%)	12 (3.04%)	0.645
ROS1 rearrangement	8 (0.85%)	6 (1.09%)	2 (0.51%)	0.480
RET rearrangement	7 (0.74%)	6 (1.09%)	1 (0.25%)	0.249
BRAF mutation	6 (0.63%)	4 (0.73%)	2 (0.51%)	1.000
HER2 mutation	9 (0.95%)	6 (1.09%)	3 (0.76%)	0.742
KRAS mutation	26 (2.75%)	17 (3.09%)	9 (2.28%)	0.454
MET aberration	7 (0.74%)	4 (0.73%)	3 (0.76%)	1.000
with brain metastases
Yes	209 (21.88%)	120 (21.78%)	89 (22.03%)	0.783
No	737 (78.12%)	431 (78.22%)	306 (77.97%)
with liver metastases
Yes	136 (14.38%)	72 (13.07%)	64 (16.20%)	0.175
no	810 (85.62%)	479 (86.93%)	331 (83.80%)
with a history of hypertension
yes	136 (14.38%)	81 (14.70%)	55 (13.92%)	0.737
no	810 (85.62%)	470 (85.30%)	340 (86.08%)
the mean duration of exposure (m)	7.54	6.98	8.31	0.121
the mean number of doses	7.64	7.53	7.81	0.364
the mean dose intensity (mg/kg)	8.07	8.37	7.64	0.823